Assyro AI

FDA Orange Book · active-ingredient family

Acetylcysteine lysine

Acetylcysteine lysine is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:LEGUBETI · NDA 215040

1

Brand (NDA)

0

Generics (ANDA)

0

Listed patents

2

Exclusivity periods

Brand (NDA) products · for solution

ProductApplicantApplicationTEApproved
LEGUBETIRLD×2GALEPHARNDA 215040Feb 13, 2024

Marketing exclusivity (2)

  • NPNew product exclusivity (3 years)

    Feb 13, 2027

    in 8 mo

  • NPNew product exclusivity (3 years)

    Feb 13, 2027

    in 8 mo

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Acetylcysteine lysine — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.